



[Home](#) / [Investors](#) / [Press Releases](#)

Insmmed to Present at UBS Global Pharmaceutical Conference May 23, 2005

RICHMOND, Va., May 19, 2005 (BUSINESS WIRE) -- Insmmed Incorporated (NASDAQ: INSM) today announced that Philip J. Young, Chief Business Officer and Executive Vice President of Commercial Operations of Insmmed, will present Monday, May 23, 2005 at 7:30am ET during the UBS Global Pharmaceutical Conference at the Grand Hyatt New York. An audio only portion of the conference presentation will be available via www.insmed.com. The audio transmission of the presentation will be available live and by replay. The replay of the presentation will begin approximately 11:00am ET and will be available until June 23, 2005.

About Insmmed

Insmmed is a biopharmaceutical company focused on the discovery and development of drug candidates for the treatment of metabolic diseases and endocrine disorders with unmet medical needs. For more information, please visit <http://www.insmed.com>.

Statements included within this press release, which are not historical in nature, may constitute forward-looking statements for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements regarding expected financial position, results of operations, cash flows, dividends, financing plans, business strategies, operating efficiencies or synergies, budgets, capital and other expenditures, competitive positions, growth opportunities for existing or proposed products or services, plans and objectives of management, demand for new pharmaceutical products, market trends in the pharmaceutical business, inflation and various economic and business trends. Such forward-looking statements are subject to numerous risks and uncertainties, including risks that product candidates may fail in the clinic or may not be successfully marketed, the company may lack financial resources to complete development of product candidates, competing products may be more successful, demand for new pharmaceutical products may decrease, the biopharmaceutical industry may experience negative market trends and other risks detailed from time to time in the company's filings with the Securities and Exchange Commission. As a result of these and other risks and uncertainties, actual results may differ materially from those described in this press release.
